ATT 1 Senior _Advisor_2026_Statement of Work - Biological therapeutics EOC Support- 7571PS27Q00017
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
OMAS STRATEGIC BUYING CENTER - PROFESSIONAL SERVICES
Contract Value
Not provided
Codes & Classification
Solicitation Number
7571PS27Q00017
NAICS
541690 - Other Scientific and Technical Consulting Services
Classification Code
R499
Additional Details
The Office of the Assistant Secretary for Financial Resources (ASFR), under the Department of Health and Human Services (HHS), through its OMAS Strategic Buying Center – Professional Services, has issued a combined synopsis/solicitation (Solicitation Number: 7571PS27Q00017) for the procurement of two Senior Advisor Consultants to support the National Institute of Neurological Disorders and Stroke (NINDS) Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) program. This opportunity is set aside exclusively for small business concerns under NAICS code 541690 (Other Scientific and Technical Consulting Services), with a small business size standard of $19 million. The place of performance is Bethesda, Maryland.
**Purpose and Scope**
The primary objective of this procurement is to secure the services of two highly experienced, executive-level consultants with deep expertise in drug discovery and development, specifically in the field of biological therapeutics. These Senior Advisors will serve as Subject Matter Experts (SMEs) on the BPN-Biologics External Oversight Committee (EOC). Their role is to provide strategic feedback and technical guidance to NIH program leadership on drug discovery and development projects within the BPN-Biologics portfolio, and, as needed, on other NIH drug discovery and development initiatives. The intended outcome is to enhance the quality, direction, and impact of NIH’s biologics development efforts through expert external oversight.
**Key Requirements and Deliverables**
- **Personnel Qualifications:** Offerors must propose two executive-level consultants with demonstrable experience in biological therapeutics and drug development. Resumes and letters of commitment for all key personnel are required, and all proposed key personnel must be employed by the offeror by the contract start date.
- **Role and Responsibilities:** The selected consultants will participate as EOC members, providing strategic and technical input on BPN-Biologics projects. This includes reviewing project progress, advising on scientific and technical challenges, and offering recommendations to NIH leadership.
- **Level of Effort:** The government anticipates approximately 50 labor hours per consultant per year, with an option for up to an additional 50 hours annually.
- **Travel:** Up to $2,000 in annual travel expenses per consultant may be reimbursed, subject to government approval and demonstrated necessity.
- **Reporting and Invoicing:** Contractors must adhere to agency invoicing instructions (Attachment 6) and comply with all reporting requirements as specified in the Statement of Work (Attachment 1).
**Contract Structure and Terms**
- **Type of Contract:** Fixed Price Purchase Order.
- **Period of Performance:** Base period from November 5, 2026, to November 4, 2027, with two one-year option periods extending through November 4, 2029. The total contract duration, including options, will not exceed three years.
- **Key Personnel Clause:** Substitution or diversion of key personnel requires prior written consent from the Contracting Officer, with at least 30 days’ advance notice when practicable.
- **Salary Cap:** No NIH funds may be used to pay direct annual salaries exceeding the Executive Schedule, Level II rate. This limitation applies to all personnel, including subcontractors and consultants.
- **Evaluation Criteria:** Proposals will be evaluated based on technical capability (with emphasis on personnel qualifications), price, and relevant past performance. Offerors must provide clear evidence of their ability to meet the technical requirements, including a narrative addressing how proposed personnel satisfy the evaluation criteria.
- **Submission Requirements:** Responses are limited to 10 single-sided pages (excluding resumes, letters of commitment, certifications, and the price template). Required attachments include a completed price template (in Excel), resumes, letters of commitment, and past performance examples.
- **SAM Registration:** Offerors must have an active registration in the System for Award Management (SAM) at the time of quote submission.
**Administrative and Compliance Considerations**
- **Set-Aside:** This procurement is set aside for SBA-certified small businesses.
- **Applicable Regulations:** The solicitation incorporates relevant FAR and HHSAR provisions and clauses by reference, including those related to information security, personnel security, and ICT accessibility.
- **Submission Deadline:** All required materials must be submitted electronically by 1:00 PM Eastern Time on November 5, 2026, referencing solicitation number 7571PS27Q00017. Questions must be submitted by October 30, 2026, at 1:00 PM EST.
- **Contacts:**
- Contract Specialist: Savada Robinson ([email protected])
- Contracting Officer: Michelle Cecilia ([email protected], 301-272-9118)
**Constant Elements Over Contract Lifecycle**
Throughout the contract, the core requirements—providing executive-level SME support to the BPN-Biologics EOC, maintaining key personnel, adhering to fixed price and labor hour limitations, and complying with federal acquisition and HHS-specific clauses—will remain unchanged. The focus on high-level scientific and technical guidance in biological therapeutics, as well as the need for clear documentation, reporting, and compliance with salary and travel policies, will be consistent throughout the contract’s duration.
**Summary for Contractors**
This opportunity is well-suited for small businesses with a proven track record in scientific and technical consulting, particularly those with access to senior-level experts in biological therapeutics and drug development. The contract requires a disciplined approach to personnel management, compliance with federal acquisition regulations, and the ability to provide strategic, high-impact advisory services to NIH leadership. Interested parties should ensure their proposed consultants meet the stringent qualifications and be prepared to demonstrate relevant past performance in similar federal or commercial engagements.
Documents6